A series of 3-(4-alkoxypheny)propanoic acid derivatives was prepared as candidate peroxisome proliferator-activated receptor (PPAR) d-selective agonists, based on our previously discovered potent human PPARa/d dual agonist TIPP-401 as a lead compound. Structure-activity relationship studies clearly indicated the importance of the chain length of the alkoxy group at the 4-position, and the n-butoxy compound exhibited the most potent PPARd transactivation activity and highest PPARd selectivity. The (S )-enantiomer of a representative compound (TIPP-204) exhibited extremely potent PPARd transactivation activity, comparable to that of the known PPARd-selective agonist GW-501516. To understand why TIPP-204 shows high selectivity for hPPARd among hPPAR subtypes, and why TIPP-401, a structurally related compound, is a hPPARa/d dual agonist, computational docking of TIPP-401 to the ligand binding domains of hPPARa and hPPARd and X-ray structure analysis of TIPP-204-hPPARd ligand binding domain were carried out. The results allowed identification of certain amino acids as putative determinants of the hPPARd selectivity of TIPP-204. To conˆrm the signiˆcance of these amino acids, GAL4-fusion proteins of mutated hPPARds and hPPARas were prepared, and the transactivation activity of TIPP-204 toward the mutants was evaluated. The amino acid(s) that predominantly in‰uence the potency and selectivity of TIPP-204 are diŠerent from that of the wellknown PPARd-selective agonist GW-501516, which belongs to a diŠerent chemical class. The signiˆcance of these amino acids was conˆrmed by the examination of the complex structure between TIPP-204 and hPPARd. The results revealed several interactions relevant to the hPPARd-selectivity of the two ligands and will be useful for logical hPPARd ligand design.
(Received January 9, 2009; Accepted February 27, 2009) A series of 3-(4-alkoxypheny)propanoic acid derivatives was prepared as candidate peroxisome proliferator-activated receptor (PPAR) d-selective agonists, based on our previously discovered potent human PPARa/d dual agonist TIPP-401 as a lead compound. Structure-activity relationship studies clearly indicated the importance of the chain length of the alkoxy group at the 4-position, and the n-butoxy compound exhibited the most potent PPARd transactivation activity and highest PPARd selectivity. The (S )-enantiomer of a representative compound (TIPP-204) exhibited extremely potent PPARd transactivation activity, comparable to that of the known PPARd-selective agonist GW-501516. To understand why TIPP-204 shows high selectivity for hPPARd among hPPAR subtypes, and why TIPP-401, a structurally related compound, is a hPPARa/d dual agonist, computational docking of TIPP-401 to the ligand binding domains of hPPARa and hPPARd and X-ray structure analysis of TIPP-204-hPPARd ligand binding domain were carried out. The results allowed identification of certain amino acids as putative determinants of the hPPARd selectivity of TIPP-204. To conˆrm the signiˆcance of these amino acids, GAL4-fusion proteins of mutated hPPARds and hPPARas were prepared, and the transactivation activity of TIPP-204 toward the mutants was evaluated. The amino acid(s) that predominantly in‰uence the potency and selectivity of TIPP-204 are diŠerent from that of the wellknown PPARd-selective agonist GW-501516, which belongs to a diŠerent chemical class. The signiˆcance of these amino acids was conˆrmed by the examination of the complex structure between TIPP-204 and hPPARd. The results revealed several interactions relevant to the hPPARd-selectivity of the two ligands and will be useful for logical hPPARd ligand design. Fig. 1）のチアゾリジン-2 Chart 2. Synthetic Route to the Optically Active Phenylpropanoic Acid Derivatives (e) (I) BnBr, KHCO 3 , DMF, rt., 85％; (II) (i) nBuI, K 2 CO 3 , DMF, rt., quant.; (f) (I) NaBH 4 , EtOH, rt., 80％; (II) PBr 3 , ether, 0°C, 65％; (g) LiHMDS, (R )-3-butyryl-4-benzyloxazolidine-2-one, THF, -30°C 0°C, 70％; (h) (I) H2, 10％Pd-C, AcOEt, rt., 90％; (II) BH3-THF, THF, 0°C -rt., quant.; (III) activatedMnO2, CH2Cl2, rt., 80％; (i) 2-‰uoro-4-tri‰uoromethylbenzamide, (Et) 3SiH, TFA, toluene, re‰ux, 75％; (j) LiOH H2O, aq-H2O2, THF-H2O, 70％; (k) LiHMDS, (S )-3-butyryl-4-benzyloxazolidine-2-one, THF, -30°C 0°C, 70％. 
Compounds were screened for agonist activity on PPAR-GAL4 chimeric receptors in transiently transfected HEK-293 cells. EC 50 value is the molar concentration of the test compound that aŠords 50％ of the maximal reporter activity detected for the positive control. Fenoˆbric acid, GW-501516 and ciglitazone served as positive control for the hPPARa, hPPARd and hPPARg transactivation assay, respectively. n＝3. 
